LIDOCAINE HYDROCHLORIDE INJECTION SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

LIDOCAINE HYDROCHLORIDE

Pieejams no:

LABORATOIRE AGUETTANT

ATĶ kods:

N01BB02

SNN (starptautisko nepatentēto nosaukumu):

LIDOCAINE

Deva:

20MG

Zāļu forma:

SOLUTION

Kompozīcija:

LIDOCAINE HYDROCHLORIDE 20MG

Ievadīšanas:

BLOCK/INFILTRATION

Vienības iepakojumā:

15G/50G

Receptes veids:

Ethical

Ārstniecības joma:

LOCAL ANESTHETICS

Produktu pārskats:

Active ingredient group (AIG) number: 0101280001; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2020-06-17

Produkta apraksts

_Lidocaine Hydrochloride Injection _
_Page 1 of 23_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Lidocaine Hydrochloride Injection
Sterile Solution, 100 mg / 5 mL (20 mg / mL), Intravenous
House Standard
Antiarrhythmic
C01BB01
Preservative-Free. Single use.
Laboratoire Aguettant
1 rue Alexander Fleming
69007 Lyon
France
Imported and Distributed by:
Aguettant Canada Inc.
1470 Peel Suite A-152
Montreal, QC, H3A 1T1
Submission Control No: 234178
Date of Initial Approval:
November 04, 2021
_Lidocaine Hydrochloride Injection _
_Page 2 of 23_
RECENT MAJOR LABEL CHANGES
Not applicable.
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES.............................................................................
2
TABLE OF CONTENTS
...................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................... 3
1
INDICATIONS.......................................................................................................
3
1.1
Pediatrics...............................................................................................................
3
1.2
Geriatrics
...............................................................................................................
3
2
CONTRAINDICATIONS.......................................................................................
3
3
DOSAGE AND ADMINISTRATION
.................................................................... 3
3.1
Dosing Considerations
.........................................................................................
3
3.2
Recommended Dose and Dosage Adjustment
................................................... 4
3.3
Administration
.......................................................................................................
4
4
OVERDOSAGE
...............................................................................